Canaccord Genuity Maintains Buy on Pacific Biosciences, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a 'Buy' rating on Pacific Biosciences (NASDAQ:PACB) but has lowered the price target from $17 to $15.

October 31, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite a lowered price target from $17 to $15, Canaccord Genuity maintains a 'Buy' rating on Pacific Biosciences.
The news is directly about Pacific Biosciences and is likely to influence investor sentiment. While the lowered price target might be seen as a negative, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100